LOXL1 and non-small cell lung carcinoma: Another group showed that in vivo non-small-cell lung cancer (NSCLC) xenograft models that overexpressed a cross-linking enzyme (LOXL1) resulted in higher collagen alignment, suggesting that increased cross-linking is a key component in NSCLC tumorigenicity [53].